M
Maria Elisa Mancuso
Researcher at Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Publications - 172
Citations - 4301
Maria Elisa Mancuso is an academic researcher from Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico. The author has contributed to research in topics: Haemophilia & Haemophilia A. The author has an hindex of 31, co-authored 146 publications receiving 3331 citations. Previous affiliations of Maria Elisa Mancuso include University of Milan.
Papers
More filters
Journal ArticleDOI
A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A
Flora Peyvandi,Pier Mannuccio Mannucci,Isabella Garagiola,Amal El-Beshlawy,Mohsen Saleh Elalfy,Vijay Ramanan,Peyman Eshghi,Suresh Hanagavadi,Ramabadran Varadarajan,Mehran Karimi,Mamta Manglani,Cecil Ross,Guy Young,Tulika Seth,Shashikant Apte,Dinesh M Nayak,E. Santagostino,Maria Elisa Mancuso,Adriana C Sandoval Gonzalez,Johnny Mahlangu,Santiago Bonanad Boix,M. Cerqueira,Nadia P. Ewing,Christoph Male,Tarek Owaidah,Veronica Soto Arellano,Nathan L Kobrinsky,Suvankar Majumdar,Rosario Perez Garrido,Anupam Sachdeva,Mindy L. Simpson,Mathew Thomas,Ezio Zanon,Bülent Antmen,Kaan Kavakli,Marilyn J. Manco-Johnson,Monica Martinez,Esperanza Marzouka,Maria Gabriella Mazzucconi,Daniela Neme,Angeles Palomo Bravo,Rogelio Paredes Aguilera,Alessandra Nunes Loureiro Prezotti,Klaus Schmitt,Brian M. Wicklund,Bulent Zulfikar,Frits R. Rosendaal +46 more
TL;DR: Patients treated with plasma-derived factor VIII containing von Willebrand factor had a lower incidence of inhibitors than those treated with recombinant factor VIII, and this association did not change in multivariable analysis.
Journal ArticleDOI
Environmental risk factors for inhibitor development in children with haemophilia A: a case–control study
Elena Santagostino,Maria Elisa Mancuso,Angiola Rocino,Giacomo Mancuso,Maria Gabriella Mazzucconi,Annarita Tagliaferri,Maria Messina,Pier Mannuccio Mannucci +7 more
TL;DR: The protective effect on inhibitor development shown by prophylaxis may represent an additional advantage prompting its use in haemophilic children.
Journal ArticleDOI
A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors.
Guy Young,Ri Liesner,Tiffany Chang,Robert F. Sidonio,Johannes Oldenburg,Víctor Jiménez-Yuste,Johnny Mahlangu,Rebecca Kruse-Jarres,Michael Wang,Marianne Uguen,Michelle Y. Doral,Lilyan Wright,Christophe Schmitt,Gallia G. Levy,Midori Shima,Maria Elisa Mancuso +15 more
TL;DR: Emicizumab prophylaxis has been shown to be a highly effective novel medication for children with hemophilia A and inhibitors and two of 88 participants developed antidrug antibodies (ADAs) with neutralizing potential, ie, associated with decreased emicIZumab plasma concentrations.
Journal ArticleDOI
Severe hemophilia with mild bleeding phenotype: molecular characterization and global coagulation profile.
Elena Santagostino,Maria Elisa Mancuso,Armando Tripodi,Veena Chantarangkul,Mario Clerici,Isabella Garagiola,P. M. Mannucci +6 more
TL;DR: These results indicate that non‐null mutations represent the main determinant of the bleeding tendency, and that ETP measurement in platelet‐rich plasma is able to identify severe hemophiliacs with a mild clinical phenotype.
Journal ArticleDOI
A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors.
Elena Santagostino,Maria Elisa Mancuso,Angiola Rocino,Giacomo Mancuso,F. A. Scaraggi,P. M. Mannucci +5 more
TL;DR: In this article, a multicenter randomized open-label crossover prospective trial was designed to compare the efficacy, safety, and cost of standard and high dosages of recombinant factor VIIa (rFVIIa) for home treatment of hemarthroses in hemophiliacs with inhibitors.